Aprea Therapeutics, Inc. · NASDAQ:APRE

Aprea Therapeutics — Investor Presentation (November 2026)

29 slides from Aprea Therapeutics's investor presentation, Nov 4, 2026

  1. Slide 1: Clinical-stage precision medicine oncology company

    1 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers November 2026

  2. Slide 2: Forward-Looking Statements

    2 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of

  3. Slide 3: 3 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved

    3 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved

  4. Slide 4: One Critical Pathway - Multiple Targets

    4 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE) One Critical Pathway - Multiple Targets 1. Ngoi N, et al. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends in Cancer. (2021); 7(10):930-957 Precision Medi

  5. Slide 5: Robust DDR Development Pipeline and Corporate Milestones 2025-2028

    5 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 2025 2026 2027 2028 H2 H1 H2 H1 H2 H1 H2 Financing WEE1 APR-1051 ATR ATRN-119 (mosipasertib) DYRK1 Inhibitor Robust DDR Development Pipeline and Corporate Milestones 2025-2028 Accomplished and anticipated milestones DNA Damage Response (DDR) *P

  6. Slide 6: Strong Drug Development and Commercial Expertise

    6 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Strong Drug Development and Commercial Expertise Experienced team in synthetic lethality and targeted therapy Management Board of Directors Richard Peters, MD, PhD Chairman of the Board Oren Gilad, PhD President and CEO Jean-Pierre Bizzari, MD

  7. Slide 7: WEE1 Inhibitor: APR-1051 Clinical Proof-Of-Concept

    7 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 7 WEE1 Inhibitor: APR-1051 ACESOT-1051: Clinical Proof-Of-Concept

  8. Slide 8: WEE1 Has Emerged as a Therapeutic Target of Significant Industry Interest

    8 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved WEE1 Has Emerged as a Therapeutic Target of Significant Industry Interest 1. Zentalis Corporate Presentation, April 2026 2. Debio 0123-101, A Phase 1 Trial of Debio 0123 In Combination With Carboplatin In Advanced Solid Tumors: Safety, Pharmaco

  9. Slide 9: ACESOT-1051: Phase 1 Study Design

    9 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved ACESOT-1051: Phase 1 Study Design Multi-center, open-label Phase 1 single-agent dose escalation and dose selection optimization Part 1 Dose escalation up to 100 patients RP2D Oral single-agent APR-1051 will be administered once-daily for 28-day

  10. Slide 10: APR-1051 Summary of Duration of Treatment

    10 © 2026 Aprea Therapeutics, Inc. All Rights Reserved 223 49 43 178 56 36 112 85 181 28 38 21 12 140 58 84 44 13 9 0 50 100 150 200 250 01-005 03-005 02-003 03-006 01-006 03-007 03-008 01-008 01-010 03-010 03-013 01-014 03-011 01-011 03-012 01-012 01-013 01-015 02-004 300 mg 220 mg 150 mg 100 mg 70

  11. Slide 11: Treatment-related AEs in Patients Treated with APR-1051

    11 © 2026 Aprea Therapeutics, Inc. All Rights Reserved MedDRA Preferred Term APR-1051 All dose levels (N=28) Treatment-related AEs, n (%)a All Grades Grade ≥ 3b Nausea 10 (35.7) 0 (0) Fatigue 4 (14.3) 0 (0) Vomiting 3 (10.7) 0 (0) Alanine aminotransferase increased 1 (3.6) 1 (3.6)c Anemia 1 (3.6) 0

  12. Slide 12: Confirmed Partial Response in Patient 01-011

    12 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Confirmed Partial Response in Patient 01-011 220mg QD – Currently on treatment Demographics: 63-year-old Black Female Site: MD Anderson Cancer Center Diagnosis: Uterine carcinosarcoma Key Mutations: PPP2R1A Treatment History (4 prior lines) • Li

  13. Slide 13: Disease Control Observed in Early Patient Outcomes

    13 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Disease Control Observed in Early Patient Outcomes APR-1051 shows preliminary evidence of disease control in rectal cancer with mutated FBXW7 100 mg Cohort Case Report Patient: 86-year-old Asian Female Diagnosis: Rectal Cancer Key Mutations: F

  14. Slide 14: Disease Control Observed in Early Patient Outcomes

    14 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 70 mg Cohort Case Report Disease Control Observed in Early Patient Outcomes Patient: 62-year-old White Male Diagnosis: HPV+ Oropharyngeal Squamous Cell Carcinoma (base of tongue) Key Mutations: P16+ Treatment History: 3 prior lines • Line 1: C

  15. Slide 15: Biomarker Defined Registration Path

    15 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Biomarker Defined Registration Path *Data as of May 6, 2026 and are preliminary from an ongoing dose-escalation study. Responses and stable disease require confirmation in additional patients and may change as follow-up matures. Safety and eff

  16. Slide 16: APR-1051: Potentially Differentiated WEE1 Inhibitor

    16 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 16 APR-1051: Potentially Differentiated WEE1 Inhibitor

  17. Slide 17: APR-1051: Potentially Best-in-Class WEE1 Inhibitor

    17 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Potentially Best-in-Class WEE1 Inhibitor Structurally differentiated: high potency, limited off-target inhibition design compared to other molecules AstraZeneca Adavosertib (AZD-1775) Zentalis Azenosertib (ZN-c3) Aprea APR-1051 Undis

  18. Slide 18: Pharmacokinetics of Adavosertib and Azenosertib

    18 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Pharmacokinetics of Adavosertib (AZD1775) and Azenosertib (ZN-c3) Takebe et al., Clinical Cancer Research 2021 Zentalis Pharmaceuticals, Inc. FORM 10-K For the fiscal year ended December 31, 2021 • Median Tmax: 1 to 4 hours (fasted) • Cmax and

  19. Slide 19: APR-1051 Concentrations by Dose Level

    19 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051 Concentrations in Cycle 1 and Cycle 2 by Dose Level

  20. Slide 20: APR-1051: Potent WEE1 Inhibitor, Limited PLK Inhibition

    20 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Potentially Best-in-Class WEE1 Inhibitor Potent inhibitor of WEE1 Does not substantially inhibit structurally and functionally related PLK1, PLK2 or PLK3 -10 -9 -8 -7 -6 -5 -4 0 25 50 75 100 125 PLK1 IC50 Determination Log10 [conc] (

  21. Slide 21: PLK1 Inhibition Counteracts Effect of WEE1 Inhibitors

    21 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved PLK1 Inhibition Counteracts Effect of WEE1 Inhibitors1 Minimal PLK1 co-inhibition enhances therapeutic window for APR-1051 37 nM 111 nM 333 nM 1 µM 37 nM 111 nM 333 nM 1 µM Phos-H2AX Control (MCM3) NT Phos-CDK1 APR-1051 75 nM GSK-PLKi Control

  22. Slide 22: PLK1 Suppression and Sepsis-Induced Loss of Intestinal Barrier Function

    22 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Studies Show PLK1 Suppression is Associated with Sepsis-Induced Loss of Intestinal Barrier Function 1 PLK1 protects against sepsis-induced intestinal barrier dysfunction, Cao et al, Scientific Reports (2018). 2 PLK1 protects intestinal barrier

  23. Slide 23: APR-1051 Showed Preclinical Activity in Combination Across Multiple Cancer Models

    23 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved HPV+ Cancer – Collaboration with MD Anderson Ovarian Cancer* UMSCC47 tumor cells OVCAR3 tumor xenograft Tumor Volume (mm3 ) Vehicle Aprea ATRi 30 mg/kg QD Aprea WEE1i 30 mg/kg QD Combination – half dose, 15mg/kg each Days Post Treatment Tumor

  24. Slide 24: APR-1051 WEE1 Summary

    24 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Clinically validated target • WEE1 inhibitors have shown promising activity in genomically defined tumors • Competitor programs constrained by low therapeutic window APR-1051 clinical highlights • Preliminary clinical proof-of-concept at 150 m

  25. Slide 25: Intellectual Property Portfolio, Financial Summary & Capitalization, Investment Highlights

    25 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 25 Intellectual Property Portfolio Financial Summary & Capitalization Investment Highlights

  26. Slide 26: Robust Global Intellectual Property Protection

    26 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust Global Intellectual Property Protection Family 1 Ataxia Telangiectasia and Rad3-Related (ATR) Protein Kinase Inhibitors • Macrocyclic inhibitors of ATR & methods of using them to treat various cancers, filed on Oct. 13th, 2015 • Patents

  27. Slide 27: Financial Summary and Capitalization

    27 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Securities Common Equivalents as of November 4, 2026 Preferred Stock (as converted) 15,596 Common Stock1 14,191,136 Pre-Funded Warrants 39,799,626 Purchase Warrants 45,844,103 Milestone Warrants 2,194,788 Options 1,107,804 Restricted Stock Uni

  28. Slide 28: Investment Highlights

    28 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Expected cash runway into Q1 2028 • Achieve near term inflection points and catalysts • Evaluate optimal strategic partnerships Near term catalysts • APR-1051: Q4 2026 Interim clinical data; Q2 2027 Complete dose escalation enrollment • ATRN-1

  29. Slide 29: Aprea Therapeutics

    29 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE)

Aprea Therapeutics — Investor Presentation (November 2026) on 6ix